Information de reference pour ce titreAccession Number: | 00005792-201710130-00013.
|
Author: | He, Jin Peng MD *; Feng, Jie Xiong PhD *
|
Institution: | Department of Pediatric Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
|
Title: | Two-incision laparoscopic appendectomy for a severe hemophilia A child patient with coagulation factor VII deficiency: Case report and review of literature.[Article]
|
Source: | Medicine. 96(41):e8197, October 2017.
|
Abstract: | Rationale: The main complication of patients with severe hemophilia is recurrent bleeding events that usually affected musculoskeletal contractures. And replacement therapy methods were continuously improved to minimize adverse impacts brought by those complications. However, only several cases reported about the appendectomy for hemophilia A. We report a case of acute appendicitis treated by two-incision laparoscopy in a boy with hemophilia A and coagulation factor VII deficiency for the first time.
Patient concerns: An 8y7m-old Chinese boy presented with half a day of right sided abdominal pain, fever, nausea, and vomiting.
Diagnoses: He received a computed tomography (CT) scan which revealed an enlarged appendix, thickened wall and appendiceal fecalith, and had received a conservative anti-bacterial treatment for his acute appendicitis but failed. He was diagnosed with hemophilia A and coagulation factor VII deficiency.
Interventions: Two-incision laparoscopic appendectomy was made in success with a careful management of perioperative period. We monitored the clotting factor FVIII level and gave him a replacement therapy.
Outcomes: The patient had an uneventful recovery.
Lessons: It is important to exclude intraabdominal or retroperitoneal hemorrhage in patients suffering from hemophilia and acute abdominal pain. Pre-operative evaluation of validity of the FVIII replacement therapy is another effective strategy to assess the safety and feasibility of applying an operation procedure. The two-incision laparoscopic appendectomy is an effective treatment for this kind of patients for its minimal trauma and fast recovery characteristics. Our report shows that laparoscopic appendectomy is feasible in a child suffering from hemophilia after adequate blood clotting factor replacement treatment.
Copyright (C) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.
|
Author Keywords: | appendectomy; child; coagulation factor VII deficiency; hemophilia A; laparoscopy.
|
References: | [1]. Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet 2016;388:187-97.
[2]. Aarabi S, Sidhwa F, Riehle KJ, et al. Pediatric appendicitis in New England: epidemiology and outcomes. J Pediatr Surg 2011;46:1106-14.
[3]. Addiss DG, Shaffer N, Fowler BS, et al. The epidemiology of appendicitis and appendectomy in the United States. Am J Epidemiol 1990;132:910-25.
[4]. Sivit CJ. Imaging the child with right lower quadrant pain and suspected appendicitis: current concepts. Pediatr Radiol 2004;34:447-53.
[5]. Aziz O, Athanasiou T, Tekkis PP, et al. Laparoscopic versus open appendectomy in children: a meta-analysis. Ann Surg 2006;243:17-27.
[6]. Guana R, Lonati L, Garofalo S, et al. Laparoscopic versus open surgery in complicated appendicitis in children less than 5 years old: a six-year single-centre experience. Surg Res Pract 2016;2016:4120214.
[7]. Redwine J, Bold RJ. Perioperative care of the patient with hemophilia undergoing urgent appendectomy. Arch Surg 2007;142:894-7.
[8]. Simic D, Milojevic I. The intraoperative use of recombinant FVIIa in child with hemophilia A with antibodies. Paediatr Anaesth 2007;17:789-92.
[9]. Gein VV, Malykh NN. [Treatment of hemorrhage following appendectomy in a child with hemophilia]. Khirurgiia 1985;7:139-40.
[10]. Fijnvandraat K, Cnossen MH, Leebeek FW, et al. Diagnosis and management of haemophilia. BMJ 2012;344:e2707.
[11]. Trossaert M, Lienhart A, Nougier C, et al. Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements. Haemophilia 2014;20:550-8.
[12]. Jacquemin M, Lavend'homme R, Benhida A, et al. A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor. Blood 2000;96:958-65.
[13]. Mannucci PM, Shi Q, Bonanad S, et al. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development. Haemophilia 2014;20(Suppl 6):2-16.
[14]. Bastida JM, Gonzalez-Porras JR, Jimenez C, et al. Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes. Thromb Haemost 2017;117:66-74.
[15]. Carkman S, Ozben V, Saribeyoglu K, et al. Spontaneous intramural hematoma of the small intestine. Ulus Travma Acil Cerrahi Derg 2010;16:165-9.
[16]. McCoy HE 3rd, Kitchens CS. Small bowel hematoma in a hemophiliac as a cause of pseudoappendicitis: diagnosis by CT imaging. Am J Hematol 1991;38:138-9.
[17]. Arpaci T, Sasmaz I, Akbas T, et al. Bilateral recurrent external obturator muscle hematoma: an unusual cause of pelvic pain in hemophilia. Mol Clin Oncol 2016;4:622-4.
[18]. Janic D, Smoljanic Z, Krstovski N, et al. Ruptured intramural intestinal hematoma in an adolescent patient with severe hemophilia A. Int J Hematol 2009;89:201-3.
[19]. Koyama T, Nagao T, Tsunozaki H, et al. Successful management of massive intraperitoneal bleeding in a hemophilia A patient with inhibitor by surgical debridement of the incomplete hematoma and administration of recombinant factor VIII and activated factor VII. Pathophysiol Haemost Thromb 2006;35:405-7.
[20]. Miano DI, Silvis RM, Popp JM, et al. Abdominal CT does not improve outcome for children with suspected acute appendicitis. West J Emerg Med 2015;16:974-82.
[21]. Akhtar W, Ali S, Arshad M, et al. Focused abdominal CT scan for acute appendicitis in children: can it help in need? J Pak Med Assoc 2011;61:474-6.
[22]. Dubb S, Arnold A, Banavali S, et al. Acute appendagitis presenting with features of appendicitis: value of abdominal CT evaluation. Case Rep Gastroenterol 2008;2:191-5.
[23]. Leissinger CA, Singleton T, Kruse-Jarres R. How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors. Blood 2015;126:153-9.
[24]. Kempton CL, Meeks SL. Toward optimal therapy for inhibitors in hemophilia. Blood 2014;124:3365-72.
[25]. Gomez K, Klamroth R, Mahlangu J, et al. Key issues in inhibitor management in patients with haemophilia. Blood Transfus 2014;12(suppl 1):s319-29.
[26]. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007;109:4648-54.
[27]. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013;19:e1-47.
[28]. Hermans C, Altisent C, Batorova A, et al. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia 2009;15:639-58.
[29]. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007;5:1904-13.
[30]. Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2014;20:65-72.
[31]. Fridberg MJ, Hedner U, Roberts HR, et al. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul Fibrinolysis 2005;16:259-66.
[32]. Bysted BV, Scharling B, Moller T, et al. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. Haemophilia 2007;13:527-32.
[33]. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Therapeut 1994;55:638-48.
[34]. Villar A, Aronis S, Morfini M, et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004;10:352-9.
[35]. Varadi K, Negrier C, Berntorp E, et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003;1:2374-80.
[36]. Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood 2016;127:1633-41.
|
Language: | English.
|
Document Type: | Research Article: Clinical Case Report.
|
Journal Subset: | Nursing. Clinical Medicine. Health Professions. Pharmacology.
|
ISSN: | 0025-7974
|
NLM Journal Code: | mny, 2985248r
|
DOI Number: | https://dx.doi.org/10.1097/MD.00...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|